Immunalon

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameImmunalon
Drug Alias Nametriple 4-1BB costimulator/IL-2/IL-12 (Provecs)IL-2, IL-12 and CD137 ligand-expressing immunostimulant (Provecs)
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionInterleukin-12 receptor stimulantsInterleukin-2 receptor agonistsTumor necrosis factor receptor superfamily member 9 stimulants
TargetsInterleukin-2 receptorInterleukin-12 receptorTumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesProvecs Medical GmbH
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesProvecs Medical GmbH
Active IndicationsN/A
Inactive IndicationsSolid tumoursUrinary Bladder NeoplasmsLiver Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A